Akebia Therapeutics, Inc.
AKBA
$3.19
$0.072.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.47M | 57.34M | 46.50M | 37.43M | 43.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.47M | 57.34M | 46.50M | 37.43M | 43.65M |
| Cost of Revenue | 10.72M | 8.16M | 8.13M | 5.92M | 8.30M |
| Gross Profit | 51.76M | 49.17M | 38.37M | 31.51M | 35.35M |
| SG&A Expenses | 26.56M | 25.74M | 27.68M | 26.52M | 26.92M |
| Depreciation & Amortization | -- | -- | 9.01M | 9.01M | 9.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.28M | 43.66M | 56.60M | 49.93M | 51.87M |
| Operating Income | 14.19M | 13.68M | -10.10M | -12.51M | -8.23M |
| Income Before Tax | 247.00K | 6.11M | -22.80M | -20.04M | -8.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 247.00K | 6.11M | -22.80M | -20.04M | -8.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 247.00K | 6.11M | -22.80M | -20.04M | -8.58M |
| EBIT | 14.19M | 13.68M | -10.10M | -12.51M | -8.23M |
| EBITDA | 14.51M | 13.99M | -754.00K | -3.13M | 1.19M |
| EPS Basic | 0.00 | 0.03 | -0.10 | -0.10 | -0.04 |
| Normalized Basic EPS | 0.00 | 0.02 | -0.05 | -0.06 | -0.02 |
| EPS Diluted | 0.00 | 0.03 | -0.10 | -0.10 | -0.04 |
| Normalized Diluted EPS | 0.00 | 0.02 | -0.05 | -0.06 | -0.02 |
| Average Basic Shares Outstanding | 262.57M | 235.50M | 218.70M | 210.35M | 209.71M |
| Average Diluted Shares Outstanding | 271.10M | 241.60M | 218.70M | 210.35M | 209.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |